AP NEWS

Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments” report has been added to ResearchAndMarkets.com’s offering.

Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis report covers 12 drugs currently in different phases of development

The report provides Mucopolysaccharidosis III treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are Alexion Pharmaceuticals, Omeros Corporation among others.

Key Topics Covered:

1. Introduction

1.1. Research Methodology

1.2. Research Scope

1.2.1. Analysis by Company

1.2.2. Analysis by Phase

1.2.3. By Molecule Type

1.2.4. By region

2. Disease Overview

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

5.2.1. Phase of Development

5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)

5.3. By Molecule type

5.4. Analysis by Region

6. Company profiling

BioMarin Pharmaceutical UniQure Biopharma B.V. Swedish Orphan Biovitrum Abeona Therapeutics Lysogene Phoenix Nest Inc. Orchard Therapeutics ArmaGen Esteve Oxford BioMedica Plc Axcentua

For more information about this report visit https://www.researchandmarkets.com/research/2d8c9r/mucopolysaccharido?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006401/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Clinical Trials,Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:38 PM/DISC: 06/05/2018 12:38 PM

http://www.businesswire.com/news/home/20180605006401/en

AP RADIO
Update hourly